Actively Recruiting
Study of Ultrasound-Enhanced Delivery of Tranexamic Acid and Reduced Glutathione for Treating Melasma in Adults Aged 20 to 55
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2025-11-25
35
Participants Needed
1
Research Sites
2 weeks
Total Duration
AI-Summary
What This Trial Is About
Melasma is a localized skin disorder causing light to dark brown patches on the face. Researchers are evaluating the effectiveness and safety of a compound solution containing 10% tranexamic acid and 2% reduced glutathione delivered via ultrasound in treating melasma. This study uses a split-face controlled trial design to compare treatments and is led by The First Affiliated Hospital with Nanjing Medical University. Participants will receive topical applications of the compound solution applied with ultrasound at either 5Wcm8 for 10 minutes or without ultrasound for 10 minutes. The study compares the enhanced delivery of the solution by ultrasound versus standard topical application. Treatment lasts 8 weeks with follow-ups at 4 and 12 weeks after the final intervention. During the study, participants will undergo evaluations including measurement of melasma severity using hemi-MASI scores, patient self-assessments, clinical efficacy reviews, VISIA digital skin analysis, and quality of life questionnaires. These assessments occur at enrollment, during treatment, at the end of treatment, and during follow-up visits. The study monitors safety and treatment effects over the full course of participation, which extends beyond the 8-week treatment period to include post-treatment observations.
CONDITIONS
Brief Title
Ultrasound-Enhanced Delivery of Compound TXA Solution in Melasma
Research Team
L
Lu Yan, phD
L
Lu Yan, phD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here